{"id":46042,"date":"2025-01-10T18:15:50","date_gmt":"2025-01-10T17:15:50","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=46042"},"modified":"2026-10-07T17:20:45","modified_gmt":"2026-10-07T15:20:45","slug":"eu-seeks-harmonisation-of-privilege-for-generic-market-entry-managing-ip-2024","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/de\/publikationen\/eu-seeks-harmonisation-of-privilege-for-generic-market-entry-managing-ip-2024\/","title":{"rendered":"EU seeks harmonisation of privilege for generic market entry, Managing IP 2025"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.maiwald.eu\/de\/team\/christian-meyer\/\" data-type=\"link\" data-id=\"https:\/\/www.maiwald.eu\/de\/team\/christian-meyer\/\">Dr. Christian Meyer<\/a> untersucht die vorgeschlagenen \u00c4nderungen der neuen EU-Bestimmungen, die den schnelleren Markteintritt von Generika und Biosimilars erleichtern sollen, um angeblich den Wettbewerb zu st\u00e4rken und den Zugang der Patienten zu verbessern.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-46042","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/46042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":4,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/46042\/revisions"}],"predecessor-version":[{"id":59090,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/46042\/revisions\/59090"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/media?parent=46042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}